Change in Polistemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials
TURKISH JOURNAL OF HEMATOLOGY（2023）
摘要
Ropeginterferon alfa-2b (RopegIFN) enables effective cytoreduction in polycythemia vera (PV). Recent analyses suggest that long-term RopegIFN therapy fulfills treatment goals important to patients with PV including good quality of life, the slowing of disease progression, and long event-free survival. Data support the use of RopegIFN in both early PV therapy and second-line and beyond.
更多查看译文
关键词
PH-negative chronic myeloproliferative neoplasm,Chronic myeloproliferative neoplasms,Neoplasia,Hematopoietic stem and progenitor cells,Hematopoiesis,Pharmacotherapeutics,Neoplasia,Oncogenes
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要